Randomized trial: No benefit from discontinuing ACE Inhibitors and ARBs in patients admitted with COVID-19

Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial – JAMA

Commentary: Discontinuing vs. Continuing ACEIs, ARBs in Patients Admitted With COVID-19 – American College of Cardiology

Related study (study and commentary): Randomized trial: Renin–angiotensin system inhibitors can be safely continued in patients admitted to hospital with COVID-19